신경 영상 진단 소프트웨어 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the neurological imaging software market size is expected to grow from USD 1.76 billion in 2025 to USD 2.02 billion in 2026 and is forecast to reach USD 3.61 billion by 2031 at 12.33% CAGR over 2026-2031.

This report is Segmented by Software Type (Integrated, Standalone), Imaging Modality (MRI, CT, PET, SPECT, EEG/MEG, Others), Application (Diagnostics, Research, Others), Deployment (On-Premises, Cloud-Based, Hybrid), End User (Hospitals, Imaging Centers, Research Institutes, Pharma/Biotech, Others), and Geography (North America, Europe, Asia Pacific, Middle East, South America)

Global Neurological Imaging Software Market Trends and Insights

Rising Disease Burden Extends the Per-Patient Imaging Window

The neurological imaging software market benefits from a growing need to manage long-duration neurological conditions. A 2026 study covering 470 million people in 38 countries found that neurological disability remained high even as age-adjusted death rates declined, particularly for Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. These conditions often require repeated MRI examinations over many years. A patient with multiple sclerosis or Alzheimer's disease may therefore generate serial imaging needs rather than one diagnostic scan. The World Stroke Organization projects a 58% increase in prevalent stroke cases worldwide by 2050. Providers that support brain volume measurement, lesion tracking, and progression review can serve this repeated clinical demand within the neurological imaging software market.

AI-Assisted Quantification Reshapes Neuroradiology Workflow Economics

The neurological imaging software market is also advancing as clinical teams seek to shorten routine interpretation work. AI tool availability in United States neuroradiology practices rose from 24.7% in 2017 to 61.4% in 2024, according to a 2025 survey. The same survey found that 78.7% of neuroradiologists had at least 1 burnout symptom, while 38.6% reported an intention to retire earlier than planned. Software must reduce routine work without creating false-positive review burdens for specialists. The long-running gap between neuroradiology job listings and trained graduates adds urgency to practical quantification tools. Siemens Healthineers received FDA 510(k) clearance for AI-Rad Companion Brain MR in January 2026, demonstrating continued institutional interest in automated quantitative brain MRI analysis.

Legacy System Integration Costs Create a Structural Adoption Barrier

The neurological imaging software market faces a practical constraint in the integration of new tools with existing systems. Hospitals must connect AI applications with PACS, DICOM-SR, HL7 FHIR, and electronic health records that may use incompatible data models. This work can require custom middleware and delay clinical activation by 6 to 18 months. The burden is more pronounced for regional hospitals in Europe and Asia Pacific that operate older PACS infrastructure. GE HealthCare received FDA clearance for its cloud-native View diagnostic viewer, which is intended to create a unified workflow across locations. Even where the technology reduces friction, hospitals must still train clinical and information technology staff and validate each tool against local equipment and protocols.

Other drivers and restraints analyzed in the detailed report include:

1. Cloud-Native Platforms Enable Multi-Site Clinical and Research Collaboration
2. Imaging Biomarkers in CNS Drug Development Create a New Software Demand Category
3. Regulatory Evidence Demands Limit Generalizability of Neuroimaging AI

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Integrated software held 68.5% of revenue in 2025. It fits hospital environments where radiologists, neurologists, and neurosurgeons need to share data in one workflow. The neurological imaging software market therefore continues to favor platform continuity in large health systems. Siemens Healthineers introduced Syngo Flexinity at ECR 2025 as a subscription suite for MRI, CT, and AI applications across scanner fleets. The model reduces separate licensing decisions for individual applications. It also gives providers a path to future software updates.

Standalone software is projected to grow at a 12.4% CAGR from 2026 to 2031. Buyers who manage Alzheimer's trial cohorts or multiple sclerosis monitoring may select specialized tools for strong performance in a single clinical task. The neurological imaging software industry can therefore support specialist modules alongside integrated systems. These modules are usually added to an existing workflow rather than used to replace the core imaging platform. This creates room for OEM suppliers and focused software firms to serve the same hospital account. It also makes evidence for a specific disease indication an important part of procurement decisions.

MRI software held 42.2% of revenue in 2025, the largest neurological imaging software market size among imaging modalities. MRI is used across stroke, tumors, epilepsy, multiple sclerosis, and neurodegenerative disease assessment. PET software is forecast to grow at a 13.3% CAGR through 2031. Its adoption is tied to quantitative amyloid and tau biomarker assessment in treatment programs and clinical studies. CT software remains important in acute stroke triage, where time to treatment is critical. Harrison.ai received FDA clearance in March 2026 for acute infarct triage on non-contrast CT across 6 vascular territories.

SPECT software retains a defined role in perfusion imaging and epileptic focus localization. EEG and MEG visualization software is gaining use in pediatric epilepsy centers and pre-surgical mapping. These tools can support source localization where structural MRI alone is insufficient. Multimodal software and functional near-infrared spectroscopy software remain earlier-stage areas of the neurological imaging software market. Academic centers and cognitive neuroscience laboratories are expanding these capabilities for differentiated research use. The resulting demand is more specialized than the broad demand for MRI and CT analysis, but it provides suppliers with opportunities in focused clinical and research settings.

Complete Report Scope:

• Software Type
  • Integrated Software
  • Standalone Software
• Imaging Modality
  • MRI Software
  • CT Software
  • PET Software
  • SPECT Software
  • EEG and MEG Visualization and Analysis Software
  • Others (fNIRS Software, Multimodal Neuroimaging Software, etc)
• Application
  • Clinical Diagnostics
  • Research Applications
  • Others (Drug Development, Clinical Trials, etc.)
• Deployment
  • On-Premises
  • Cloud-Based
  • Hybrid
• End User
  • Hospitals and Health Systems
  • Diagnostic Imaging Centers
  • Academic Medical Centers and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Others (Contract Research Organizations, Specialty Neurology and Neurosurgery Clinics)
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East
    • GCC
    • South Africa
    • Rest of Middle East
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.1% of global revenue in 2025, the leading neurological imaging software market share by region. The United States has a dense base of academic medical centers and a high number of FDA-cleared neuroimaging AI products. Siemens, GE HealthCare, Aidoc, Viz.ai, RapidAI, and Cercare Medical obtained new clearances between January and June 2026. The FDA Software as a Medical Device framework offers an established route for suppliers entering the United States. Medicare and commercial reimbursement for advanced neuroimaging also supports provider adoption. Canada's telestroke networks and Mexico's growing private neurology sector add regional demand, although the United States remains the main volume center.

Europe is the second-largest regional area for the neurological imaging software market. Germany, the United Kingdom, and France are the main demand centers. EU AI Act and Medical Device Regulation requirements have raised validation expectations for neuroimaging tools. Suppliers that meet those requirements can gain credibility in broader European procurement. Germany-based mediaire and VEObrain serve clinical users in DACH markets, while EBRAINS supports multi-country research under common data governance. The United Kingdom National Health Service is engaging with international vendors, including Heuron, while France, Italy, and Spain provide active academic neurology networks.

Asia Pacific is forecast to grow at a 12.6% CAGR from 2026 to 2031, the fastest regional growth rate in the neurological imaging software market. Japan uses a PMDA-regulated pathway that has supported domestic neuroimaging AI products. LPixel received PMDA approval in June 2025 for an EIRL Brain Aneurysm model update that reduced false positives and reported 92.3% sensitivity. FUJIFILM Healthcare launched SYNAPSE SAI viewer Ver2.6 in Japan in January 2025 with 3 brain MRI reading support functions. China's UII system automatically segments 111 brain regions, while South Korea's Neurophet is expanding after a third FDA 510(k) clearance in January 2026. India and Australia are building demand through academic neuroscience investment and healthcare digitization, while GCC countries, Brazil, and Argentina offer longer-term opportunities constrained by infrastructure and reimbursement gaps.

1. Siemens Healthineers
2. GE HealthCare Technologies Inc.
3. Koninklijke Philips
4. Canon
5. Agfa-Gevaert
6. FUJIFILM Healthcare Corporation
7. Brain Lab
8. MIM Software
9. QMENTA Inc.
10. Viz.ai Inc.
11. Aidoc Medical Ltd.
12. RapidAI Inc.
13. TeraRecon Inc.
14. Pro Medicus Limited
15. Novarad
16. Esaote S.p.A.
17. AQUILAB
18. IXICO
19. Brainomix Ltd.
20. Quibim S.L.
21. Pixyl SAS
22. Imaging Biometrics, LLC
23. NeuroLogica

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Burden of Stroke, Dementia, Multiple Sclerosis, Epilepsy, Brain Tumors, and Traumatic Brain Injury
  • 4.2.2 AI-Assisted Quantification and Shorter Neurological Imaging Turnaround Times
  • 4.2.3 Expansion of Cloud-Native Imaging and Cross-Site Neuroimaging Data Collaboration
  • 4.2.4 Growing Demand for Imaging Biomarkers in Precision Neurology and CNS Clinical Trials
  • 4.2.5 Rising Need to Standardize Longitudinal Brain Measurement Across Scanners and Sites
  • 4.2.6 Neurovascular Care Coordination and Time-to-Treatment Optimization
• 4.3 Market Restraints
  • 4.3.1 High Integration, Validation, and Lifecycle Cost Across Legacy PACS, EHR, and Modalities
  • 4.3.2 Regulatory and Evidence Burden for Generalizable Neuroimaging AI
  • 4.3.3 Inter-Scanner, Protocol, and Population Variability That Weakens Algorithm Reproducibility
  • 4.3.4 Shortage of Neuro-Radiology, Imaging Informatics, and AI Validation Expertise
• 4.4 Value and Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces Analysis

5 MARKET SIZE AND GROWTH FORECASTS

• 5.1 Software Type
  • 5.1.1 Integrated Software
  • 5.1.2 Standalone Software
• 5.2 Imaging Modality
  • 5.2.1 MRI Software
  • 5.2.2 CT Software
  • 5.2.3 PET Software
  • 5.2.4 SPECT Software
  • 5.2.5 EEG and MEG Visualization and Analysis Software
  • 5.2.6 Others (fNIRS Software, Multimodal Neuroimaging Software, etc)
• 5.3 Application
  • 5.3.1 Clinical Diagnostics
  • 5.3.2 Research Applications
  • 5.3.3 Others (Drug Development, Clinical Trials, etc.)
• 5.4 Deployment
  • 5.4.1 On-Premises
  • 5.4.2 Cloud-Based
  • 5.4.3 Hybrid
• 5.5 End User
  • 5.5.1 Hospitals and Health Systems
  • 5.5.2 Diagnostic Imaging Centers
  • 5.5.3 Academic Medical Centers and Research Institutes
  • 5.5.4 Pharmaceutical and Biotechnology Companies
  • 5.5.5 Others (Contract Research Organizations, Specialty Neurology and Neurosurgery Clinics)
• 5.6 Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Siemens Healthineers AG
  • 6.3.2 GE HealthCare Technologies Inc.
  • 6.3.3 Koninklijke Philips N.V.
  • 6.3.4 Canon Medical Systems Corporation
  • 6.3.5 Agfa-Gevaert Group
  • 6.3.6 FUJIFILM Healthcare Corporation
  • 6.3.7 Brainlab AG
  • 6.3.8 MIM Software Inc.
  • 6.3.9 QMENTA Inc.
  • 6.3.10 Viz.ai Inc.
  • 6.3.11 Aidoc Medical Ltd.
  • 6.3.12 RapidAI Inc.
  • 6.3.13 TeraRecon Inc.
  • 6.3.14 Pro Medicus Limited
  • 6.3.15 Novarad Corporation
  • 6.3.16 Esaote S.p.A.
  • 6.3.17 AQUILAB SAS
  • 6.3.18 IXICO plc
  • 6.3.19 Brainomix Ltd.
  • 6.3.20 Quibim S.L.
  • 6.3.21 Pixyl SAS
  • 6.3.22 Imaging Biometrics, LLC
  • 6.3.23 NeuroLogica Corporation

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment
• 7.2 Future Outlook